<DOC>
	<DOCNO>NCT00693771</DOCNO>
	<brief_summary>Primary objective : To show improvement HbA1c control 4 month treatment insulin glargine + Oral Anti Diabetic ( OAD ) patient previously uncontrolled premixed insulin ( OAD ) Secondary objective : Improvement Fasting blood glucose ( FPG ) 4 month treatment ( % patient treat target HbA1c ≤7.0 % and/or FBG≤6.0mmol/L ) . Frequency hypoglycemic episode , quality life basal+ OAD regimen .</brief_summary>
	<brief_title>Study Optimize Insulin Treatment Basal Regimen With Insulin Glargine Type-2-Diabetic Patients Previously Uncontrolled Premixed Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients Type 2 Diabetes Mellitus inadequately control least 3 month premixed insulin 1 2 OADs 7.5 ≤ HbA1c ≤ 9.5 % FPG ≥6.7 mmol/L History Diabetes mellitus ≤10 year Premix insulin daily dosage ≤ 50 IU/Day Type 1 Diabetes Mellitus Former treat TZD Pregnancy / Lactation Creatine ≥1.5 mg/dl Hepatic disease , jaundice , ALT/AST≥ 2.5 time normal range Hormone therapy , Acute status Diabetes complication Severe concomitant disease complication high risk unexpected fatal event , like Myocardial Infarct , stroke , heart failure . Allergic insulin glargine ingredient Participation another clinical trial within 3 month The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>